SA519410259B1 - مركب كبير الحلقات واستخداماته - Google Patents

مركب كبير الحلقات واستخداماته

Info

Publication number
SA519410259B1
SA519410259B1 SA519410259A SA519410259A SA519410259B1 SA 519410259 B1 SA519410259 B1 SA 519410259B1 SA 519410259 A SA519410259 A SA 519410259A SA 519410259 A SA519410259 A SA 519410259A SA 519410259 B1 SA519410259 B1 SA 519410259B1
Authority
SA
Saudi Arabia
Prior art keywords
macrocyclic compound
pharmaceutically acceptable
compound
caf
activity
Prior art date
Application number
SA519410259A
Other languages
English (en)
Inventor
كين ايتو
كازونوبو كيرا
يوشيتو كيشى
Original Assignee
ايساى ار اند دى ماناجيمينت كو. ليمتد
بريسيدنت اند فيلوس اوف هارفارد كوليج
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by ايساى ار اند دى ماناجيمينت كو. ليمتد, بريسيدنت اند فيلوس اوف هارفارد كوليج filed Critical ايساى ار اند دى ماناجيمينت كو. ليمتد
Publication of SA519410259B1 publication Critical patent/SA519410259B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب جديد (1) يشتمل على تأثير إعادة قولبة وعائية للورم tumor vascular remodeling effect و/أو النشاط المضاد لخلايا أرومية ليفية مرتبطة بالسرطان Cancer Associated Fibroblasts (CAF)، أو ملح مقبول صيدلانياً منه وبشكل اختياري المادة الحاملة المقبولة صيدلانياً والاستخدامات الطبية لها. المركب (1). شكل1
SA519410259A 2017-04-05 2019-10-06 مركب كبير الحلقات واستخداماته SA519410259B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (1)

Publication Number Publication Date
SA519410259B1 true SA519410259B1 (ar) 2022-09-11

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410259A SA519410259B1 (ar) 2017-04-05 2019-10-06 مركب كبير الحلقات واستخداماته

Country Status (33)

Country Link
US (2) US11725015B2 (ar)
EP (2) EP3606928B1 (ar)
JP (4) JP7168580B2 (ar)
KR (2) KR102634732B1 (ar)
CN (2) CN110831946B (ar)
AU (2) AU2018250147B2 (ar)
BR (1) BR112019020208A2 (ar)
CA (1) CA3056945A1 (ar)
CL (1) CL2019002854A1 (ar)
CO (1) CO2019011538A2 (ar)
DK (1) DK3606928T3 (ar)
EC (1) ECSP19075677A (ar)
ES (1) ES2931533T3 (ar)
HR (1) HRP20221385T1 (ar)
HU (1) HUE060466T2 (ar)
IL (2) IL288991B2 (ar)
JO (1) JOP20190234B1 (ar)
LT (1) LT3606928T (ar)
MA (1) MA48027B1 (ar)
MD (1) MD3606928T2 (ar)
MX (1) MX2019011982A (ar)
PE (1) PE20200602A1 (ar)
PH (1) PH12019502197A1 (ar)
PL (1) PL3606928T3 (ar)
PT (1) PT3606928T (ar)
RS (1) RS63755B1 (ar)
SA (1) SA519410259B1 (ar)
SG (1) SG11201908603PA (ar)
SI (1) SI3606928T1 (ar)
TW (1) TWI781163B (ar)
UA (1) UA124399C2 (ar)
WO (1) WO2018187331A1 (ar)
ZA (1) ZA201906279B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
SG11201912342QA (en) * 2017-07-06 2020-01-30 Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CN117924310A (zh) * 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
CA2935786C (en) 2004-06-03 2019-02-12 Eisai R & D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
ES2503395T3 (es) 2007-03-07 2014-10-06 Interdigital Technology Corporation Método y aparato para generar y tratar una unidad de datos de protocolo MAC-ehs
CA2690449A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
MX2010003599A (es) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediarios y metodos para la sintesis de analogos de halicondrina b.
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
RU2517167C2 (ru) 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
EP2663337A4 (en) 2011-01-10 2014-06-11 Harvard College METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
IN2014MN01521A (ar) 2011-12-29 2015-05-01 Alphora Res Inc
AU2013239290B2 (en) 2012-03-30 2017-08-03 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein
JP2016500112A (ja) * 2012-11-30 2016-01-07 ハンジョウ ジロックス ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｚｙｌｏｘ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． ラパマイシン類似体及びその製作方法
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
CN105431438A (zh) 2013-07-03 2016-03-23 阿方拉研究股份有限公司 用于制备软海绵素b 的大环c1-酮基类似物的合成方法和可用于其中的中间体、包括含有-so2-(对甲苯基)基团的中间体
EP3066102B1 (en) * 2013-11-04 2020-02-26 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG11201604545XA (en) 2013-12-06 2016-07-28 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
WO2016003975A1 (en) * 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN117024469A (zh) 2015-05-07 2023-11-10 卫材R&D管理有限公司 可用于合成软海绵素大环内酯的大环化反应以及中间体和其他片段
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US20210187059A1 (en) 2017-02-20 2021-06-24 Polyphor Ag Pharmaceutical combinations for treating cancer
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
SG11201912342QA (en) 2017-07-06 2020-01-30 Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CN117924310A (zh) 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途

Also Published As

Publication number Publication date
SG11201908603PA (en) 2019-10-30
HUE060466T2 (hu) 2023-03-28
PT3606928T (pt) 2022-12-05
IL269788B (en) 2022-01-01
TW201902902A (zh) 2019-01-16
US20210261566A1 (en) 2021-08-26
AU2018250147B2 (en) 2022-09-29
PL3606928T3 (pl) 2023-02-06
SI3606928T1 (sl) 2023-02-28
JP2024028872A (ja) 2024-03-05
WO2018187331A1 (en) 2018-10-11
RS63755B1 (sr) 2022-12-30
US11725015B2 (en) 2023-08-15
CA3056945A1 (en) 2018-10-11
AU2022291454B2 (en) 2024-03-28
JOP20190234A1 (ar) 2019-10-03
CL2019002854A1 (es) 2019-12-27
CO2019011538A2 (es) 2020-02-28
EP3606928A1 (en) 2020-02-12
AU2022291454A1 (en) 2023-02-16
RU2019135531A3 (ar) 2021-09-07
PH12019502197A1 (en) 2020-12-07
ECSP19075677A (es) 2020-01-31
CN115093429A (zh) 2022-09-23
JP2022153392A (ja) 2022-10-12
IL288991B1 (en) 2023-08-01
ZA201906279B (en) 2021-01-27
CN110831946B (zh) 2022-06-21
JP6366873B1 (ja) 2018-08-08
JOP20190234B1 (ar) 2023-09-17
DK3606928T3 (da) 2022-11-28
EP3606928B1 (en) 2022-09-07
BR112019020208A2 (pt) 2020-04-22
TW202321259A (zh) 2023-06-01
CN110831946A (zh) 2020-02-21
WO2018187331A8 (en) 2018-12-06
JP7168580B2 (ja) 2022-11-09
LT3606928T (lt) 2022-12-12
EP4119563A3 (en) 2023-04-05
JP2020513021A (ja) 2020-04-30
ES2931533T3 (es) 2022-12-30
MA48027B1 (fr) 2022-12-30
TWI781163B (zh) 2022-10-21
IL288991A (en) 2022-02-01
IL288991B2 (en) 2023-12-01
UA124399C2 (uk) 2021-09-08
JP7400025B2 (ja) 2023-12-18
KR20190137121A (ko) 2019-12-10
KR20240023674A (ko) 2024-02-22
IL269788A (en) 2019-11-28
PE20200602A1 (es) 2020-03-10
EP4119563A2 (en) 2023-01-18
RU2019135531A (ru) 2021-05-05
JP2018177774A (ja) 2018-11-15
US20230406863A1 (en) 2023-12-21
MD3606928T2 (ro) 2022-12-31
AU2018250147A1 (en) 2019-10-03
MX2019011982A (es) 2019-11-08
KR102634732B1 (ko) 2024-02-13
HRP20221385T1 (hr) 2023-01-06

Similar Documents

Publication Publication Date Title
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
WO2019099646A8 (en) Macrocyclic compounds and uses thereof
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2019003938A (es) Compuestos espirociclicos.
MY198605A (en) Maytansinoid derivatives conjugates thereof, and methods of use
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NZ754865A (en) Combination therapy for the treatment of cancer
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
TN2019000211A1 (en) Antitumoral compounds
PH12017500881B1 (en) Aurora a kinase inhibitor
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2017014436A (es) Compuestos biciclicos.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MX2019005504A (es) Potenciadores de bmp.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
EA201992372A1 (ru) Макроциклическое соединение и его применения
ZA202105931B (en) Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer